Third Rock rolls $47m dice on cancer immunotherapy and Jounce 'dream team'

As one of the founders and the sole funder for Jounce Therapeutics' $47 million Series A venture funding round, Third Rock Ventures has placed a big bet on cancer immunotherapies, but the firm is working with a group of clinicians and researchers hand-picked to ensure that at least some of Jounce's wagers pay off.

The Cambridge, Massachusetts-based company's mission is to discover and develop first-in-class immunotherapies that harness patients' immune systems to seek and destroy cancerous cells and tumors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

07 May 2025

• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

07 May 2025

• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.